Glucose control in patients with type 2 diabetes based on frequency of insulin glargine administration

Diabetes Research and Clinical Practice

Volumn 88, Issue 2, 2010, Pages

  Housel, Audrey K ^a   Shaw, Robert F ^a   Waterbury, Nancee V ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Glucose control; Insulin glargine twice daily; Predictors; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE;

ADULT; ARTICLE; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG RESPONSE; FEMALE; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 77952885255     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2010.01.020     Document Type: Article

References (5)

1. Sanofi-Aventis U.S. LLC. Lantus® package insert, Bridgewater, NJ, March (2007).
2. Idampitiya C., Ward K., Curtis C., Fernando D.J.S., Idris I., Thomson G.A. Once daily insulin glargine may induce loss of basal insulin action in some patients with type 1 diabetes receiving basal bolus regimens: the need for twice daily glargine. Diabetes 2005, 54(Suppl. 1):A493. (abstract).
3. Albright E.S., Desmond R., Bell D.S.H. Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy. Diabetes Care 2004, 27(2):632-633. (letter).
4. Stratton I.M., Adler A.I., Neil H.A.W., Matthews D.R., Manley S.E., Cull C.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405-412.
5. McCord A.D., Kiel P.J., Deurloo D., Zgarrick D.P. Insulin glargine: clinical efficacy and predictors of twice daily dosing. Pharmacotherapy 2005, 25(10):1454. (abstract 99).